Skip to main content
MedVellum
QuestionsVideosPricing

MedVellum

Fellowship exam preparation across every specialty: source-verified topics, questions in every format, and videos.

Product

  • Specialties
  • Questions
  • Videos
  • Exam tools
  • Pricing

Verification & policy

  • Verified register
  • Editorial policy
  • Privacy
  • Terms

Account

  • Sign in
  • Create account
  • Dashboard
  • Account & billing

© 2026 MedVellum. For education only — not a substitute for clinical judgement.

llms.txtPsychiatry LLM catalogSitemap

Paeds Vivasallergy-and-immunology

Paeds Vivas · allergy-and-immunology

Anaphylaxis prevention, action plans and autoinjectors — branching viva

Branching structured-oral viva on the community anaphylaxis prevention package: the pharmacology of adrenaline and why the intramuscular outer-thigh route, the weight-band transitions for autoinjector dosing, the biphasic reaction and the mandatory observation window, school readiness and the education ladder, and the fatal-risk triad of adolescence with peanut or tree-nut allergy and uncontrolled asthma — covering adrenaline-first reasoning, the green-to-red escalation, and adolescent transition.

branching clinical structured oral6 min readVerification in progress

Target exams

RACP DCEMRCPCH ClinicalRCPSC Pediatrics
On this page
Study tools

Target exams

RACP DCEMRCPCH ClinicalRCPSC Pediatrics
Prompt
You are the general paediatric registrar in the outpatient clinic. A 7-year-old boy weighing 23 kg is reviewed after an anaphylactic reaction to peanut at school last week. The examiner asks you to take the candidate through the prevention prescription, the adrenaline pharmacology and route, the weight-band dosing decision, the biphasic observation pathway, and how the plan would change if the patient were a 16-year-old who does not carry his device.

Opening question

Examiner: Take me through this boy. What is your frame for the prevention prescription, and what are you going to write today? [1]

Candidate: My frame is that a child at risk of anaphylaxis is kept alive by a package, not by a single intervention, and the visit today is about building that package so it travels with him. He has had a confirmed anaphylactic reaction to peanut, so he is at risk of recurrence, and my job is to make sure that the next reaction is survivable wherever it happens. The package has six components: confirmed trigger avoidance, the green and red ASCIA action plans, the weight-appropriate adrenaline autoinjector, two devices and a trainer, rehearsed education of every carer, and optimised asthma control with a review date. I am going to write all six today, because any one of them alone is insufficient. [10]

Examiner: Why two plans rather than one? [10]

Candidate: Because decision plan exists to make is when to cross from a mild reaction to anaphylaxis, and the colour coding removes that deliberation at the moment of crisis. The green plan covers mild-to-moderate reactions — skin and mild gut symptoms — where the carer gives an antihistamine and watches closely for escalation. The red plan triggers adrenaline the moment anaphylaxis is recognised: any airway or breathing problem, collapse or pallor, or a rapid reaction involving skin plus another body system. The carer does not diagnose; they read the colour, and that single design feature is what makes the plan usable under stress by a non-clinician. [10]

Paediatrics Fellowship Pro

Continue reading

You have read the opening of this viva. The complete unit — every section and its primary-source references — is part of the Paediatrics Fellowship fellowship library.

Sign in to continueSee pricing
References9ShowHide
  1. [1]Sampson HA; Muñoz-Furlong A; Campbell RL; et al Second symposium on the definition and management of anaphylaxis: summary report--Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol, 2006.PMID 16461139
  2. [2]Brown SG Clinical features and severity grading of anaphylaxis. J Allergy Clin Immunol, 2004.PMID 15316518
  3. [3]Simons FE; Ardusso LR; Bilò MB; et al; World Allergy Organization 2012 Update: World Allergy Organization Guidelines for the assessment and management of anaphylaxis. Curr Opin Allergy Clin Immunol, 2012.PMID 22744267
  4. [4]Shaker MS; Wallace DV; Golden DBK; et al Anaphylaxis-a 2020 practice parameter update, systematic review, and Grading of Recommendations, Assessment, Development and Evaluation (GRADE) analysis. J Allergy Clin Immunol, 2020.PMID 32001253
  5. [9]Simons FE First-aid treatment of anaphylaxis to food: focus on epinephrine. J Allergy Clin Immunol, 2004.PMID 15131564
  6. [10]Sicherer SH; Simons FER; SECTION ON ALLERGY AND IMMUNOLOGY Epinephrine for First-aid Management of Anaphylaxis. Pediatrics, 2017.PMID 28193791
  7. [11]Turner PJ; Jerschow E; Umasunthar T; Lin R; Campbell DE; Boyle RJ Fatal Anaphylaxis: Mortality Rate and Risk Factors. J Allergy Clin Immunol Pract, 2017.PMID 28888247
  8. [12]Lee S; Bellolio MF; Hess EP; et al Time of Onset and Predictors of Biphasic Anaphylactic Reactions: A Systematic Review and Meta-analysis. J Allergy Clin Immunol Pract, 2015.PMID 25680923
  9. [13]Mehr S; Liew WK; Tey D; Tang ML Clinical predictors for biphasic reactions in children presenting with anaphylaxis. Clin Exp Allergy, 2009.PMID 19486033
Paediatrics Fellowship Pro

$29/ monthor $279 / year

The complete Paediatrics Fellowship library, every exam format, one subscription.

  • Complete library for one chosen specialty
  • Timed MCQ mock exams and spaced review
  • Clinical cases & cross-table vivas
See pricingSign in
PreviousAllergic rhinitis and rhinoconjunctivitis — vivaallergy-and-immunologyNextAnaphylaxis: recognition and emergency management — branching vivaallergy-and-immunology